Molly Henderson
CIK 1363812 · CFO and CBO · last filed 2025-04-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.12M
Companies
6
Total Filings
51
Lifetime Open-Market Net
-$429.5K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PHAT | CFO and CBO | 91,779 | $10.37 | $951.8K | -$447.0K | 22 | 2025-04-08 |
| URGN | Chief Financial Officer | 5,579 | $29.72 | $165.8K | $6.0K | 6 | 2022-02-02 |
| Ayala Pharmaceuticals, Inc. (ADXS) Delisted | Executive Vice President & CFO | 5,833 | $0.60 | $3.5K | $0 | 5 | 2020-05-05 |
| Ayala Pharmaceuticals, Inc. (ADXSW) Delisted | Executive Vice President & CFO | 5,000 | — | — | $0 | 2 | 2018-06-13 |
| IOVANCE BIOTHERAPEUTICS, INC. (LBIO) Delisted | CFO | — | — | — | $0 | 4 | 2016-06-15 |
| VirtualScopics, Inc. (VSCP) Delisted | Chief Business/Financial Off. | 14,400 | — | — | $11.6K | 12 | 2013-02-11 |
Recent Filings · Page 3 of 6
51 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-05-16 | PHAT | Buy (P) | +6,000 | $0 | EDGAR |
| 2022-04-06 | PHAT | Grant (A) | +20,000 | $0 | EDGAR |
| 2022-02-02 | URGN | Mixed | +335 | -$2.5K | EDGAR |
| 2021-12-02 | URGN | Mixed | +2,413 | -$31.1K | EDGAR |
| 2021-06-08 | URGN | Grant (A) | — | $0 | EDGAR |
| 2021-05-18 | URGN | Buy (P) | +2,500 | $39.6K | EDGAR |
| 2021-02-02 | URGN | Grant (A) | — | $0 | EDGAR |
| 2020-10-05 | URGN | Grant (A) | — | $0 | EDGAR |
| 2020-05-05 | Ayala Pharmaceuticals, Inc. (ADXS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-10-25 | Ayala Pharmaceuticals, Inc. (ADXS) Delisted | Grant (A) | — | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.